Brian Lian - 04 Jan 2024 Form 4 Insider Report for SEELOS THERAPEUTICS, INC.

Reporting relationship: Director
Issuer ticker: N/A
Reported as of: 04 Jan 2024
Net transaction value: $0
SEC form: 4
Accepted by SEC: 08 Jan 2024, 21:45:30 UTC
Prior SEC filing: 04 Jan 2024
Next SEC filing: 30 Jan 2024
Source filing: View source filing
Reporting owner signature: /s/ Michael Golembiewski, as attorney-in-fact for Brian Lian

Key filing fact

Brian Lian filed Form 4 for SEELOS THERAPEUTICS, INC. on 08 Jan 2024.

Key facts

This page summarizes Brian Lian's Form 4 filing for SEELOS THERAPEUTICS, INC..
1 reported transaction and 1 derivative row are listed below.
Accepted by SEC: 08 Jan 2024, 21:45.

Change

Previous filing in this sequence was filed on 04 Jan 2024.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

SEEL transaction Derivative

Stock Option (right to buy)

Award

Transaction value: $0
Shares: +1,666
Change %
Price: $0.000000
Shares after: 1,666
Date: 04 Jan 2024
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 1,666
Exercise price: $1.33
Footnotes: F1

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 1 footnote

Footnote F1

1/12th of the shares subject to the option shall vest on February 4, 2024, and 1/12th of the shares subject to the option shall vest monthly thereafter.